Vertex presents positive data for zimislecel in type 1 diabetes at the american diabetes association 85th scientific sessions

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced simultaneous presentation and publication of updated data from the phase 1/2 portion of the phase 1/2/3 forward-101 clinical trial of zimislecel (vx-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (t1d) with impaired hypoglycemic awareness and severe hypoglycemic events (shes). the data were featured in an oral presentation at the americ.
VRTX Ratings Summary
VRTX Quant Ranking